No black box warning on record for Emtricitabine/tdf

As of the latest FDA labeling reviewed, Emtricitabine/tdf (EMTRICITABINE/TDF) does not carry a black box warning. Standard warnings and precautions still apply — see the full Emtricitabine/tdf medicine page for the complete safety profile.

Other warnings & precautions

5.1 Severe Acute Exacerbation of Hepatitis B in Individuals with HBV Infection All individuals should be tested for the presence of chronic hepatitis B virus (HBV) before or when initiating emtricitabine and tenofovir disoproxil fumarate [see DOSAGE AND ADMINISTRATION (2.1)]. Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in HBV-infected

No black box warning on record for Emtricitabine/tdf

Other warnings & precautions

5.1 Severe Acute Exacerbation of Hepatitis B in Individuals with HBV Infection All individuals should be tested for the presence of chronic hepatitis B virus (HBV) before or when initiating emtricitabine and tenofovir disoproxil fumarate [see DOSAGE AND ADMINISTRATION (2.1)]. Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in HBV-infected

Emtricitabine/tdf Black Box Warning

No black box warning on record for Emtricitabine/tdf

Other warnings & precautions

Emtricitabine/tdf Black Box Warning

No black box warning on record for Emtricitabine/tdf

Other warnings & precautions